Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ • Healthcare
Last close at November 6, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 12
in 5 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Arrowhead Pharmaceuticals’ fiscal third quarter of 2026 results, reported August 4, showed a sharp revenue increase year over year, but EPS trailed consensus. Revenue rose 171% to roughly $75.3 million (up from about $27.8 million a year ago), while the company posted a net loss of about $194.3 million, widening by 11% year over year from roughly $175.2 million. On the bottom line, EPS was -$1.36 versus a -$1.28 estimate, trailed by -6.3%, and compared with -$1.26 a year ago (down 8% year over year). Profitability remained negative, with an operating loss of roughly $170.1 million, even as gross profit matched revenue at about $75.3 million. The company also paid roughly $38.4 million in dividends during the quarter. Consensus for the next period calls for EPS of USD -1.52 on revenue of USD 71.8 million.
Next report — what to expect
Arrowhead Pharmaceuticals, Inc. (ARWR) reports earnings on November 24, 2026. Wall Street’s next-period consensus calls for EPS of -$1.518 on revenue of $61.2 million. For trailing context, revenue grew +171.0% year over year last quarter. ARWR has beaten EPS in 2 of 8 most recent quarters.
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a biotechnology company that develops RNA interference medicines for complex diseases, with activity centered in the United States. In FY2025, the company recorded $829.4 million in revenue as it advanced a pipeline spanning liver, cardiometabolic, pulmonary, oncology, neuromuscular, inflammatory, and infectious-disease programs.
Today's Snapshot
ARWR closed 1.2% higher at 58.16, while its sector was flat. Arrowhead Pharmaceuticals refinanced $400 million. Earnings are due from ARWR on 12 November.
Trading Volume
Below 10d avg (1.4M)
1.3M
vs S&P 500 Today
Outperforming Market
+0.82%
Updated: November 6, 2026 at 21:17 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$59.23 - $69.84Sell
- RSI (14)39.65Neutral
- Stochastic %K (14, 3, 3)49.15Neutral
- MACD Level (12, 26)-1.91Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.